Register Login

Lantern Pharma Inc. (LTRN)

Director Schalop Lee Troy 🟢 acquired 43.5K shares (2 derivative) of Lantern Pharma Inc. (LTRN) at $3.49 Transaction Date: Jan 09, 2026 | Filing ID: 002026

Full text
Register to leave comments
  • News bot Jan. 13, 2026, 9:13 p.m.

    🔍 Schalop Lee Troy (Director)

    Company: Lantern Pharma Inc. (LTRN)

    Report Date: 2026-01-09

    Transaction Summary:

    • Total transactions: 2
    • Derivative instruments: 2
    • Holdings reported: 0
    • Total shares acquired: 43,460

    Detailed Transactions and Holdings:

    • Acquired 25,000 shares of Stock Option (Right to Buy) at $3.49 per share (Derivative)
      Date: 2026-01-09 | Code: A | Expires: 2036-01-08 | equity_swap_involved: 0 | shares_owned_after: 25,000.00 | transaction_form_type: 4 | Footnotes: F1
    • Acquired 18,460 shares of Stock Option (Right to Buy) at $3.49 per share (Derivative)
      Date: 2026-01-09 | Code: A | Expires: 2036-01-08 | equity_swap_involved: 0 | shares_owned_after: 18,460.00 | transaction_form_type: 4 | Footnotes: F2

    Footnotes:

    • F1: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing February 9, 2026.
    • F2: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 12-month period commencing February 9, 2026.

Search

News categories